More tools:Markets·Screener·Research·Chat

BioAtla, Inc. Common Stock (BCAB) Financial Statements

BioAtla, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00Y6GBV39
XNAS · usd
1.26▼ 0.06 (-4.55%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close1.32
Day's Range1.16 – 1.45
52-Week Range0.12 – 6.52
Volume40.0K
Avg Volume98.0K
Share Statistics
Shares Outstanding
Employees41
ExchangeXNAS
Listed2020-12-16
Share count as of August 10, 2026
Loading Income Statement…
Key questions about BioAtla, Inc. Common Stock (BCAB)
What is BioAtla, Inc. Common Stock's Market Cap?
BioAtla, Inc. Common Stock's Market Cap is $2.1M, based on as-reported figures from SEC (XBRL) filings.
What is BioAtla, Inc. Common Stock's Enterprise Value?
BioAtla, Inc. Common Stock's Enterprise Value is $555.3K, based on as-reported figures from SEC (XBRL) filings.
What is BioAtla, Inc. Common Stock's EV / EBITDA?
BioAtla, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is BioAtla, Inc. Common Stock's Net Income (TTM)?
BioAtla, Inc. Common Stock's Net Income (TTM) is -$31.5M, based on as-reported figures from SEC (XBRL) filings.
What is BioAtla, Inc. Common Stock's EBITDA?
BioAtla, Inc. Common Stock's EBITDA is -$31.9M, based on as-reported figures from SEC (XBRL) filings.
What is BioAtla, Inc. Common Stock's Diluted EPS (TTM)?
BioAtla, Inc. Common Stock's Diluted EPS (TTM) is -18.88, based on as-reported figures from SEC (XBRL) filings.
What is BioAtla, Inc. Common Stock's Net Debt?
BioAtla, Inc. Common Stock's Net Debt is -$1.5M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration and other revenue—
Operating expenses:
Research and development expense (includes related party amounts of $975 for the three and six months ended June 30, 2026 and $0 for the three and six months ended June 30, 2025)
General and administrative expense
Total operating expenses
Income (loss) from operations
Other income (expense):
Interest income
Gain (loss) on warrant liability
Gain on PPAs liability——
Other expense
Total other income (expense)
Net income (loss) and comprehensive income (loss)
Net income (loss) per common share, basic
Net income (loss) per common share, diluted